PA8549901A1 - Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales - Google Patents
Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronalesInfo
- Publication number
- PA8549901A1 PA8549901A1 PA20028549901A PA8549901A PA8549901A1 PA 8549901 A1 PA8549901 A1 PA 8549901A1 PA 20028549901 A PA20028549901 A PA 20028549901A PA 8549901 A PA8549901 A PA 8549901A PA 8549901 A1 PA8549901 A1 PA 8549901A1
- Authority
- PA
- Panama
- Prior art keywords
- treatment
- spinal
- brain
- receiver
- magnesium salt
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 230000001537 neural effect Effects 0.000 title abstract 3
- 210000004556 brain Anatomy 0.000 title abstract 2
- 230000006378 damage Effects 0.000 title abstract 2
- 159000000003 magnesium salts Chemical class 0.000 abstract 3
- 239000002131 composite material Substances 0.000 abstract 1
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000003405 preventing effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
LA INVENCION SE REFIERE AL USO DE UN ANTAGONISTA DEL RECEPTOR NK-1, EN COMBINACION OPCIONALMENTE CON UNA SAL DE MAGNESIO, PARA EL TRATAMIENTO Y/O PREVENCION DE LESIONES CEREBRALES, ESPINALES O NEURONALES, EN DONDE DICHO ANTAGONISTA DEL RECEPTOR NK-1 ES UN COMPUESTO DE FORMULA GENERAL I, EN DONDE LOS SIGNIFICADOS DE R, R1, R2, R2', R3, R4 SE EXPLICAN EN LA ESPECIFICACION Y LAS SALES DE ADICION ACIDA FARMACEUTICAMENTE ACEPTABLES Y LOS PRO-FARMACOS DE LOS MISMOS TANTO SOLOS O EN COMBINACION CON UNA SAL DE MAGNESIO. SE EJEMPLIFICA EL USO DE N-(3,5,-BIS-TRIFLUOROMETIL-BENCIL)-N-METIL-6-(4-METIL-PIPERAZIN-1-IL)-4-O-TOLIL-NICOTINAMIDA. LA INVENCION TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNO O MAS DE TALES ANTAGONISTAS DEL RECEPTOR NK-1, EN COMBINACION OPCIONALMENTE CON UNA SAL DE MAGNESIO, Y UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE PARA EL TRATAMIENTO Y/O PREVENCION DE LESIONES CEREBRALES, ESPINALES O NEURONALES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01116812 | 2001-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8549901A1 true PA8549901A1 (es) | 2003-01-24 |
Family
ID=8178001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20028549901A PA8549901A1 (es) | 2001-07-10 | 2002-07-05 | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales |
Country Status (24)
Country | Link |
---|---|
US (3) | US20030083345A1 (es) |
EP (2) | EP1621195A3 (es) |
JP (1) | JP2004536119A (es) |
KR (1) | KR100589106B1 (es) |
CN (1) | CN100346789C (es) |
AR (1) | AR037008A1 (es) |
AU (1) | AU2002328837B2 (es) |
BR (1) | BR0210893A (es) |
CA (1) | CA2451566C (es) |
GT (1) | GT200200143A (es) |
HK (1) | HK1068266A1 (es) |
HR (1) | HRP20031071A2 (es) |
HU (1) | HUP0401210A3 (es) |
IL (1) | IL159350A0 (es) |
MX (1) | MXPA04000278A (es) |
NO (1) | NO332847B1 (es) |
NZ (1) | NZ530107A (es) |
PA (1) | PA8549901A1 (es) |
PE (1) | PE20030238A1 (es) |
PL (1) | PL211246B1 (es) |
RU (1) | RU2304435C2 (es) |
UY (1) | UY27374A1 (es) |
WO (1) | WO2003006016A2 (es) |
ZA (1) | ZA200400138B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002006236A1 (en) * | 2000-07-14 | 2002-01-24 | F. Hoffmann-La Roche Ag | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
JP4490421B2 (ja) * | 2003-07-03 | 2010-06-23 | エフ.ホフマン−ラ ロシュ アーゲー | 統合失調症を処置するデュアルnk1/nk3アンタゴニスト |
GB0410215D0 (en) * | 2004-05-07 | 2004-06-09 | Lescroart Pol | Nerve damage |
JP4580426B2 (ja) | 2004-07-06 | 2010-11-10 | エフ.ホフマン−ラ ロシュ アーゲー | Nk−1受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法 |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
JP4767973B2 (ja) * | 2005-02-22 | 2011-09-07 | エフ.ホフマン−ラ ロシュ アーゲー | Nk1アンタゴニスト |
EP1855655A2 (en) | 2005-02-25 | 2007-11-21 | F. Hoffmann-Roche AG | Tablets with improved drug substance dispersibility |
RU2404969C2 (ru) * | 2005-03-23 | 2010-11-27 | Ф. Хоффманн-Ля Рош Аг | Метаболиты антагонистов nk-1 против рвоты |
SI2395002T1 (sl) | 2005-11-08 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
DE102007018151A1 (de) * | 2007-04-16 | 2008-10-23 | Günenthal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrのモジュレーター |
CA2700477A1 (en) * | 2007-07-19 | 2009-01-22 | Adelaide Research & Innovation Pty Ltd | Method for reducing intracranial pressure |
PL2639223T3 (pl) | 2007-12-07 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych |
SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
CA2931134C (en) | 2008-02-28 | 2019-07-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与 |
EP3016658A4 (en) * | 2013-07-02 | 2017-03-15 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iv |
US10729677B2 (en) * | 2013-07-02 | 2020-08-04 | Eustralis Pharmaceutical Limited (Trading As Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-I |
JP6464421B2 (ja) * | 2013-07-02 | 2019-02-06 | ユーストラリス ファーマシューティカルズ リミテッド (トレーディング アズ プレススラ ニューロ) | 慢性外傷性脳障害iiを予防及び/又は治療する方法 |
EP3067349B1 (en) | 2013-11-08 | 2018-02-28 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
RU2016122882A (ru) | 2013-11-12 | 2017-12-19 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
EP3746077A4 (en) * | 2018-02-02 | 2021-10-27 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | PARENTERAL FORMULATIONS AND USES THEREOF |
KR101970099B1 (ko) * | 2018-02-07 | 2019-04-17 | 한국과학기술연구원 | 척수 손상의 예방 및 치료용 조성물 |
KR102005019B1 (ko) * | 2018-04-04 | 2019-07-31 | 한국과학기술연구원 | 뇌졸중의 예방 및 치료용 조성물 |
CA3149980A1 (en) * | 2019-08-23 | 2021-03-04 | Pierre Vankan | Therapeutic methods and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4745123A (en) * | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
IS4208A (is) * | 1993-09-22 | 1995-03-23 | Glaxo Group Limited | 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður |
US6175013B1 (en) * | 1994-06-10 | 2001-01-16 | Eli Lilly And Company | Imidazolinyl tachykinin receptor antagonists |
US5607947A (en) * | 1995-02-21 | 1997-03-04 | Eli Lilly And Company | Pyrrolidinyl tachykinin receptor antagonists |
IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
TW382017B (en) * | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
US6214846B1 (en) * | 1997-06-27 | 2001-04-10 | Merck Sharp & Dohme Limited | Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents |
US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
AU772446B2 (en) * | 1999-02-24 | 2004-04-29 | F. Hoffmann-La Roche Ag | 3-phenylpyridine derivatives and their use as NK-1 receptor antagonists |
GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
DE60006340T2 (de) * | 1999-11-29 | 2004-09-09 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid |
AUPQ514600A0 (en) * | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
-
2002
- 2002-07-02 US US10/187,587 patent/US20030083345A1/en not_active Abandoned
- 2002-07-03 IL IL15935002A patent/IL159350A0/xx unknown
- 2002-07-03 WO PCT/EP2002/007323 patent/WO2003006016A2/en active IP Right Grant
- 2002-07-03 EP EP05017203A patent/EP1621195A3/en not_active Withdrawn
- 2002-07-03 MX MXPA04000278A patent/MXPA04000278A/es active IP Right Grant
- 2002-07-03 AU AU2002328837A patent/AU2002328837B2/en not_active Expired
- 2002-07-03 HU HU0401210A patent/HUP0401210A3/hu unknown
- 2002-07-03 EP EP02764617A patent/EP1406618A2/en not_active Withdrawn
- 2002-07-03 RU RU2004102397/15A patent/RU2304435C2/ru active
- 2002-07-03 CN CNB028135423A patent/CN100346789C/zh not_active Expired - Lifetime
- 2002-07-03 PL PL369535A patent/PL211246B1/pl unknown
- 2002-07-03 BR BR0210893-3A patent/BR0210893A/pt not_active IP Right Cessation
- 2002-07-03 NZ NZ530107A patent/NZ530107A/en unknown
- 2002-07-03 KR KR1020047000395A patent/KR100589106B1/ko active IP Right Grant
- 2002-07-03 CA CA2451566A patent/CA2451566C/en not_active Expired - Lifetime
- 2002-07-03 JP JP2003511822A patent/JP2004536119A/ja active Pending
- 2002-07-05 PA PA20028549901A patent/PA8549901A1/es unknown
- 2002-07-08 AR ARP020102546A patent/AR037008A1/es unknown
- 2002-07-08 PE PE2002000610A patent/PE20030238A1/es not_active Application Discontinuation
- 2002-07-09 UY UY27374A patent/UY27374A1/es not_active Application Discontinuation
- 2002-07-09 GT GT200200143A patent/GT200200143A/es unknown
-
2003
- 2003-12-22 HR HR20031071A patent/HRP20031071A2/xx not_active Application Discontinuation
-
2004
- 2004-01-07 NO NO20040057A patent/NO332847B1/no not_active IP Right Cessation
- 2004-01-08 ZA ZA2004/00138A patent/ZA200400138B/en unknown
-
2005
- 2005-01-17 HK HK05100430A patent/HK1068266A1/xx not_active IP Right Cessation
-
2006
- 2006-07-05 US US11/481,216 patent/US20060247240A1/en not_active Abandoned
-
2010
- 2010-09-21 US US12/886,691 patent/US20110053954A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8549901A1 (es) | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales | |
WO2006038006A3 (en) | 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders | |
PA8586401A1 (es) | 4-piperazinilbencenosulfonilindoles y uso de los mismos | |
MX2008001606A (es) | Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. | |
MY148487A (en) | Biphenyl derivatives | |
BRPI0514661B8 (pt) | antagonistas de vasopressina v1a, composição farmacêutica e uso dos referidos antagonistas | |
BR0107695A (pt) | Tratamento de dano cerebral, espinhal e a nervos | |
ECSP067082A (es) | Antagonistas de receptor de glucagon, preparacion y usos terapeuticos | |
CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
MY143391A (en) | Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4) | |
AR050208A1 (es) | Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
DOP2002000422A (es) | Agentes antibacterianos. | |
ES2179353T3 (es) | Antagonistas muscarinicos. | |
DE69838662D1 (de) | Morphinanderivate und ihre medizinische Anwendung | |
DK0738269T3 (da) | Piperidinderivater med PAF-antagonistaktivitet | |
NO20090256L (no) | Modulatorer for kjemokine reseptoraktivitet, krystallinske former og prosesser | |
DE60208178D1 (de) | Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten | |
EA200900245A1 (ru) | Модуляторы активности рецептора хемокина, кристалические формы и способ их получения | |
CL2004001347A1 (es) | Compuestos derivados de 4-[(imidazol-4il)etinil]-piridina sustituidos; procedimientos de preparacion; composicion farmaceutica; y su uso en la elaboracion de un medicamento util para el tratamiento o prevencion de trastornos inducidos por el receptor | |
ATE523488T1 (de) | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung | |
MX2008001607A (es) | Piperazinas biciclicas como antagonistas del receptor de glutamato metabotropico. | |
BR0308220A (pt) | Composição farmacêutica de um inibidor de pde4 ou pde3/4 e um antagonista de receptor de histamina | |
DK0758312T3 (da) | Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler | |
MXPA05011476A (es) | Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2. |